PTC Therapeutics EVP, CLO Mark Elliott Boulding reports $132,809 common stock sale

Bitget2026/10/07 21:20

Mark Elliott Boulding, executive vice president and chief legal officer, sold 2,073 PTC Therapeutics common shares on Oct. 5-6. Sales priced at USD 64.03 per share on Oct. 5, USD 64.16 per share on Oct. 6. Transactions followed option exercises at USD 39.42 per share for the same 2,073 shares. Directly held stake ended unchanged at 105,272 shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001578852-26-000024), on October 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail

Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.

智通财经•2026/11/09 07:32

Canaccord Genuity: Lowers Oklo's target price to $66

格隆汇•2026/11/09 07:01

Bernstein: Huang Renxun's Controversy May Increase Nvidia's Regulatory Risks, but Maintains $400 Price Target

Cointime•2026/11/09 06:43

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41